NON-small-cell lung carcinomaRAS oncogenesAlthough KRAS- activating mutations represent the most common oncogenic driver in non-small cell lung cancer (NSCLC), various attempts to inhibit KRAS failed in the past decade. KRAS mutations are associated with a poor prognosis and...
4.Aredo JV, Padda SK, Kunder CA, Han SS, Neal JW, Shrager JB, et al. Impact ofKRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung canceroutcomes. Lung Cancer. 2019;133:144–50. 5.E...
[2]E. CABALLE, N. Hernandez-Pedro, M. Ramos-Ramirez, et al. Impact of KRASG12D Subtype and Concurrent Pathogenic Mutations on Advanced Non-small Cell Lung Cancer Outcomes. 2023 WCLC.P1.08-06 [3]汪育锦,黄静宇,胡卫东,等. 2403例肺癌临床流行病学分析[J]. 国际肿瘤学杂志,2019,46(8):460-...
[4] Wei Daoyan, Wang Liang, Zuo Xiangsheng, et al. A small molecule with big impact: MRTX1133 targets the KRASG12D mutation in pancreatic cancer. Clin Cancer Res, 2023, undefined: undefined. [5] Prior Ian A, Hood Fiona E, Hartley Jam...
近日,吴一龙教授团队在JHO子刊Biomarker Research发表一篇论著《Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients》。这是迄今为止最大规模的中国NSCLC患者KRAS G12C突变的临床特征和预后价值分析。本报特别邀请文章第一作者刘思阳博士进行详细解读...
KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies Epidemiologic studies have evaluated the association between KRAS mutations and resistance to the treatment of epidermal growth factor receptor (EGFR) tyro... C Mao,LX ...
[4] Wei Daoyan, Wang Liang, Zuo Xiangsheng, et al. A small molecule with big impact: MRTX1133 targets the KRASG12D mutation in pancreatic cancer. Clin Cancer Res, 2023, undefined: undefined. [5] Prior Ian A, Hood Fiona E, Hartley James L. The Frequency of Ras Mutations in Cancer....
1.Prior IA, Hood FE, Hartley JL: The frequency of Ras mutations in cancer. Cancer Res 80:2969-2974, 2020 2. Tariq K, Ghias K: Colorectal cancer carcinogenesis: A review of mechanisms. Cancer Biol Med 13:120-135, 2016 3. Dy GK, Govindan R, Velcheti V, et al: Long-term outcomes...
[4]Anna Ketal.Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.Oncotarget.2015 Oct 6;6(30):30287-94. [5]Aron Kristof Ghimessy et al.KRAS Mutations Predict Response and Outcome in ...
1. Timothy F Burns, Hossein Borghaei, Suresh S Ramalingam. Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations. 2020 Oct 26; JCO2000744. doi: 10.1200/JCO.20.00744. 2. Amgen Submits Sotorasib New Drug Application To U.S. ...